• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Probi

Less than 1K followers
All
Webcasts
Press releases
3rd party
ShowingAll content types

Press release7/22/2025, 1:00 PM

Women's Health by Probi wins NutraIngredients-USA Award for Innovation in Women's Health

Probi
Press release5/28/2025, 6:37 AM

Probi Female wins prestigious NutraIngredients Award 2025 for innovation in women's health

Probi
Press release5/7/2025, 12:30 AM

First-of-its-kind: Nomura Dairy and Probi[ ]introduce probiotic-enhanced carrot juice to Japan

Probi

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2/3/2025, 8:20 AM

Delisting of Probi

Probi
Regulatory press release1/20/2025, 9:01 PM

Notice of Extraordinary General Meeting in Probi AB (publ)

Probi
Regulatory press release1/20/2025, 9:00 PM

Probi applies for delisting and convenes an Extraordinary General Meeting

Probi
Regulatory press release1/9/2025, 7:00 AM

Probi postpones year-end report 2024

Probi
Regulatory press release12/13/2024, 4:17 PM

Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise

Probi
Regulatory press release11/20/2024, 6:19 AM

Probi's Board comments on Symrise's public takeover offer

Probi
Regulatory press release11/13/2024, 10:00 AM

Probi CFO departure

Probi
Press release10/23/2024, 11:00 AM

Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Probi
Third party research10/23/2024, 5:24 AM

Probi: Managing costs well in Q3 - ABG

Miss on Q3 sales (-12%) and EBITDA (-10%) vs ABGSCe China faced headwinds due to macroeconomic factors EBITDA revised down by 2-3% for '24e-'26e Encouraging B2C sales efforts in the Nordics Probi reported a soft Q3'24 with sales amounting to SEK 143....

Probi
Probi, Audiocast with teleconference, Q3'24
Webcast10/22/2024, 8:00 AM

Probi, Audiocast with teleconference, Q3'24

Probi
Regulatory press release10/22/2024, 6:00 AM

Probi: Q3 2024: Tangible improvement in operations

Probi
Press release10/17/2024, 6:50 AM

Presentation of Probi's Q3 Report 2024

Probi
Press release10/16/2024, 11:30 AM

Probi partners with Global BHP BrainTrust and the FINGERS Brain Health Institute to counteract dementia

Probi
Press release10/10/2024, 7:00 AM

Nordic launch of Probi Sense - a unique dietary supplement for the mental capacity

Probi
Press release9/24/2024, 11:00 AM

New study strengthens Probi[ ][®]s L. plantarum HEAL9[®] strain in cognitive function

Probi
Third party research7/17/2024, 6:29 AM

Probi: FY'24e marks a transition to a promising future - ABG

- Beat on Q2 sales (+3%) and EBITDA (+24%) vs ABGSCe - EBITDA up 2% for '24e and 1% for '25e - Our comprehensive analysis indicates a promising long-term outlook Americas and EMEA progressed well in Q2 Probi reported a strong Q2'24 driven by growth in...

Probi
Probi, Audiocast with teleconference, Q2'24
Webcast7/16/2024, 8:00 AM

Probi, Audiocast with teleconference, Q2'24

Probi